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Beware the patient presenting with systemic inflammatory response and 
haemorrhage following pancreatic anastomotic leak
Pancreatic anastomotic failure remains a major source of morbidity and mortality following pancreaticoduodenec-
tomy and delayed haemorrhage as a further complication is often associated with greater mortality. In this issue of 
HPB, Nakahara et al. have documented the outcomes of 11 of 457 (2.4%) patients who underwent pancreaticoduo-
denectomy and subsequently presented with delayed haemorrhage. Five of the 11 patients died consequently. The 
median time to delayed haemorrhage was 18 days and all patients had been diagnosed previosuly with a grade B 
pancreatic fistula. Those who died were older, more likely to have underlying malignancy but, most importantly, 
their presenting systemic inflammatory response score and shock index at the time of bleeding was substantially 
higher than those who survived. C-reactive protein and white blood count were significantly higher in those who 
died compared to those who survived. These important findings suggest that when faced with patients who have a 
grade B pancreatic fistula and persistent systemic inflammatory response the surgical team must be vigilant regard-
ing the possibility of impending haemorrhage. Should prophylactic CT angiography be performed to detect pseu-
doaneuryms which could be treated prior to rupture? The question of whether a more aggressive approach, such 
as re-laparotomy to ensure adequate debridement, disconnection and externalisation of pancreatic remnant via a 
drain or completion pancreatectomy should be considered, especially in those patients with a herald bleed. The 
extreme mortality associated with delayed haemorrhage would suggest that a wait and watch approach is difficult 
to justify. What would be useful to know from this study but is not presented is the denominator of patients with 
grade B pancreatic fistula and systemic inflammatory response who did not develop delayed haemorrhage and 
whether any differences in CT or other clinical parameters could be determined. One would also be particularly 
interested in the microbiology profile including the presence or absence of fungi given its association with increased 
mortality in patients with infected pancreatic necrosis.
Saxon Connor
Selective or total inflow occlusion? You be the judge
The best way to control bleeding during the parenchymal transection phase of liver resection remains controversial. 
Using a selective approach to vascular inflow occlusion has the benefit of avoiding ischemia to the future liver 
remnant but does not stop cross circulation from the vascularized to the non-vascularized liver. Using total inflow 
occlusion or Pringle manouevre may control cross circulation but renders the future liver remnant temporarily 
ischemic. In this issue of HPB, Boleslawski and colleagues from Lille in France, present data from 181 patients 
undergoing right hepatectomy without portal triad clamping. Their technique combines selective right inflow 
occlusion and division of the right hepatic vein prior to parenchymal transection. Their results showed that the 
technique is possible in the majority of patients but, interestingly, a quarter of patients still required total inflow 
occlusion. While these data show promise for the technique, the strength of evidence is limited by the design of the 
study and it would have been better if patients had been randomly allocated to selective or total vascular occlusion. 
Without such quality of evidence, I suspect that individual surgeons will continue to follow their own preference. 
Single centres often struggle to answer such questions regarding surgical technique because of the disparity between 
their case volume and the sample size required to achieve adequate statistical power and avoid type 2 error. Perhaps 
the time has come for national or international collaborative research projects to address these important questions 
in HPB surgery.
Stephen J Wigmore
Multimodality imaging of pancreatic cancer
Several diagnostic modalities are available for the staging of HPB malignancies. Ideally, imaging modalities must 
achieve optimal staging at the least cost, morbidity and inconvenience for the patient. This is especially true for 
pancreatic cancer because optimal imaging can reveal resectable disease but, perhaps more importantly, advanced 
disease as well for which surgery is futile and unnecessary. Shrikhande et al. from Mumbai provide a detailed and 
evidence-based review of today’s imaging options for pancreatic cancer. The authors reviewed 66 articles from 
1990–2011 to determine the relative efficacies of multi-detector computed tomography (MDCT), magnetic reso-
nance imaging (MRI), endoscopic ultrasonography (EUS) and positron emission tomography-computed tomog-
raphy (PET-CT). While there is a complimentary value between the different imaging modalities, some specific 
patterns and recommendations emerge. MDCT with angiography appears to be the most versatile and first-utilized 
modality in pancreatic cancer. MRI is also precise and versatile, but seems to be used less often owing to availability 
and the technical expertise required. EUS emerges as a highly sensitive modality and appears especially worthwhile 
in imaging suspected but unproven tumors not readily seen on MDCT. While PET-CT is typically not necessary 
for pre-operative evaluation of otherwise resectable disease, it does offer sensitivity in revealing occult and distant 
metastatic disease in some patients. The authors provide a logical staging algorithm that incorporates the compli-
mentary strengths of the different modalities. Readers will find excellent citations provided from which they can 
learn more about comparative efficacy, important limitations and relative cost-effectiveness.
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